Abstract 1053P
Background
ICIs used across multiple disease sites including both early and advanced stage cancers. Systemic inflammatory markers including neutrophil to lymphocyte ratios (NLR), platelet to lymphocyte ratios (PLR) and lymphocyte to monocyte ratios (LMR) has been found to be prognostic across different tumor types, but less is known about their prognostic role in patients receiving ICIs. Here we used population-level administrative data to evaluate the potential association between NLR, PLR and LMR and overall survival (OS) among patients receiving ICIs.
Methods
We used administrative data deterministically linked across databases to identify a cohort of patients with solid tumors initiating ICI therapy in Ontario, Canada from June 2012 to October 2018 and obtained information on baseline demographics, clinical covariates, inflammatory markers (NLR, PLR, LMR) at the start of ICI, and overall survival (OS). We applied multivariable Cox proportional hazard models to evaluate the impact of NLR, PLR, and LMR on OS, adjusting for sex, age, cancer center, autoimmune history, recent hospitalization and comorbidity score.
Results
Among 4683 patients, median age was 67, 57% male; 46% had lung cancer, 35% melanoma, 9% renal cancers; 40% received nivolumab, 36% pembrolizumab, 17% ipilimumab. Median OS was 317 days. Using previous cutoffs in the literature, 44% of patients had a high NLR (≥ 5), 58% high PLR (≥ 200), and 60% high LMR (≥ 1.5). Among all patients, those with high NLR (aHR=1.80, 95% CI [1.65-1.97] p
Conclusions
Among cancer patients receiving ICIs, higher NLR and PLR and lower LMR were prognostic of OS across cancer types. Further studies validating their prognostic role in ICI therapy is warranted.
Legal entity responsible for the study
The authors.
Funding
ASCO / Conquer Cancer Foundation - Young Investigator Award.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1003P - A first-in-human (FIH) phase I study of IPH5301, an anti-CD73 monoclonal antibody (mAb), in patients with advanced solid tumors (AST) (CHANCES, NCT05143970)
Presenter: Mathilde Beaufils
Session: Poster session 03
1004P - Phase I/II trial of ASP1570, a novel diacylglycerol kinase ζ inhibitor, in patients with advanced solid tumors
Presenter: Daniel Olson
Session: Poster session 03
1005P - Microbial ecosystem therapeutics 4 (MET4) treatment mediates a humoral response in patients treated with immune checkpoint inhibition (ICI)
Presenter: Pavlina Spiliopoulou
Session: Poster session 03
1007P - Systemic STING agonist BI 1703880 plus ezabenlimab in patients (pts) with advanced solid tumors: Initial results from a phase Ia study
Presenter: Kevin Harrington
Session: Poster session 03
1008P - Preliminary clinical PK and PD analysis of a phase I study of ZL-1218, a humanized anti-CCR8 IgG1 antibody, in patients with advanced solid tumors
Presenter: Ignacio Gil Bazo
Session: Poster session 03
1010P - Phase I dose-escalation study of HBM1020: A novel anti-B7H7 antibody in patients with advanced solid tumors
Presenter: Jason Henry
Session: Poster session 03
1011P - Model-informed dose optimization of HFB200301, a TNFR2 agonist monoclonal antibody (mAb), in monotherapy and in combination with the anti-PD-1 mAb tislelizumab (TIS), in patients (pts) with advanced solid tumors
Presenter: Desamparados Roda Perez
Session: Poster session 03
1012P - Safety, tolerability, and efficacy of nadunolimab in combination with pembrolizumab in patients with solid tumors
Presenter: roger cohen
Session: Poster session 03
1013P - A phase I study of rivoceranib combined with nivolumab in patients with unresectable or metastatic cancer
Presenter: Neal Chawla
Session: Poster session 03